Literature DB >> 16226933

The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine.

Andreas Daiber1, Alexander Mülsch, Ulrich Hink, Hanke Mollnau, Ascan Warnholtz, Matthias Oelze, Thomas Münzel.   

Abstract

The hemodynamic and anti-ischemic effects of nitroglycerin (NTG) are rapidly blunted as a result of the development of nitrate tolerance. With initiation of NTG therapy, it is possible to detect neurohormonal activation and intravascular volume expansion. These so-called pseudotolerance mechanisms may compromise the vasodilatory effects of NTG. Long-term nitrate treatment also is associated with decreased vascular responsiveness caused by changes in intrinsic mechanisms of the tolerant vasculature itself. According to the oxidative stress concept, increased vascular superoxide (O2-) production and an increased sensitivity to vasoconstrictors secondary to activation of protein kinase C contribute to the development of tolerance. Nicotinamide adenine dinucleotide phosphate oxidase and the uncoupled endothelial nitric oxide synthase may be O2- -producing enzymes. Nitric oxide (NO) and O2-, both derived from NTG and the vessel wall, form peroxynitrite in a diffusion-limited rapid reaction. Peroxynitrite, O2-, or both may be responsible for the development of nitrate tolerance and cross-tolerance to direct NO donors (eg, sodium nitroprusside, sydnonimines) and endothelium-dependent NO synthase-activating vasodilators. Hydralazine is an efficient reactive oxygen species (ROS) scavenger and an inhibitor of O2- generation. When given concomitantly with NTG, hydralazine prevents the development of nitrate tolerance and normalizes endogenous rates of vascular O2- production. Recent experimental work has defined new tolerance mechanisms, including inhibition of the enzyme that bioactivates NTG (ie, mitochondrial aldehyde dehydrogenase isoform 2 [ALDH2]) and mitochondria as potential sources of ROS. NTG-induced ROS inhibit the bioactivation of NTG by ALDH2. Both mechanisms increase oxidative stress and impair NTG bioactivation, and now converge at the level of ALDH2 to support a new theory for NTG tolerance and NTG-induced endothelial dysfunction. The consequences of these processes for NTG downstream targets (eg, soluble guanylyl cyclase, cyclic guanosine monophosphate-dependent protein kinase), toxic effects contributing to endothelial dysfunction (eg, prostacyclin synthase inhibition) and novel applications of the antioxidant properties of hydralazine are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226933     DOI: 10.1016/j.amjcard.2005.07.030

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

Review 1.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 2.  Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

3.  Hydralazine and organic nitrates restore impaired excitation-contraction coupling by reducing calcium leak associated with nitroso-redox imbalance.

Authors:  Raul A Dulce; Omer Yiginer; Daniel R Gonzalez; Garrett Goss; Ning Feng; Meizi Zheng; Joshua M Hare
Journal:  J Biol Chem       Date:  2013-01-14       Impact factor: 5.157

4.  Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite.

Authors:  Abdul R Maher; Sayqa Arif; Melanie Madhani; Khalid Abozguia; Ibrar Ahmed; Bernadette O Fernandez; Martin Feelisch; A G O'Sullivan; Arthur Christopoulos; Aaron L Sverdlov; Doan Ngo; Rustem Dautov; Philip E James; John D Horowitz; Michael P Frenneaux
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

5.  Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats.

Authors:  Frederic Pinaud; Arnaud Bocquet; Odile Dumont; Kevin Retailleau; Christophe Baufreton; Ramaroson Andriantsitohaina; Laurent Loufrani; Daniel Henrion
Journal:  Hypertension       Date:  2007-05-07       Impact factor: 10.190

6.  Lipid peroxidation scavengers prevent the carbonylation of cytoskeletal brain proteins induced by glutathione depletion.

Authors:  Oscar A Bizzozero; Savanna Reyes; Jennifer Ziegler; Suzanne Smerjac
Journal:  Neurochem Res       Date:  2007-06-06       Impact factor: 3.996

7.  Continuous transdermal nitroglycerin therapy for menopausal hot flashes: a single-arm, dose-escalation trial.

Authors:  Alison J Huang; Steven R Cummings; Michael Schembri; Eric Vittinghoff; Peter Ganz; Deborah Grady
Journal:  Menopause       Date:  2016-03       Impact factor: 2.953

Review 8.  Targeting nitric oxide with drug therapy.

Authors:  R Preston Mason; John R Cockcroft
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

9.  Direct Antioxidant Properties of Bilirubin and Biliverdin. Is there a Role for Biliverdin Reductase?

Authors:  Thomas Jansen; Andreas Daiber
Journal:  Front Pharmacol       Date:  2012-03-16       Impact factor: 5.810

10.  Berberine Reverses Nitroglycerin Tolerance through Suppressing Protein Kinase C Alpha Activity in Vascular Smooth Muscle Cells.

Authors:  Huina Zhang; Jinghui Dong; Chi-Wai Lau; Yu Huang
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-28       Impact factor: 3.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.